|
|
|
|
|
HONG KONG, Apr 14, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. ("Majeton"), has entered into an exclusive Distribution Agreement with Osteopore Limited ("Osteopore") to promote and sell Osteopore's dental and oral maxillofacial products ("Products") in Singapore.
Pursuant to the Distribution Agreement, Majeton will be the exclusive distributor of the Products for an initial period of 3 years, starting from 2023 to 2026.
Osteopore's innovative oral maxilla facial products are used in guided bone regeneration, immediate implant loading, and socket preservation. In unique situations, Osteopore may also make available customised regenerative implants for various oral maxillofacial reconstructions.
The Group believes that Majeton's strong commercial presence in Singapore will synergistically bring to market Osteopore's innovative products supported by advanced 3D printing technology for improved clinical outcomes in dental patients throughout Singapore's dental clinics, private and public hospitals.
About Osteopore
Osteopore is an Australian and Singapore-based medical technology company commercialising bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.
About Essex (Stock Code: 1061.HK)
Essex Bio-Technology Limited is a biopharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun (Iodized Lecithin Capsules) etc.. The products of the Company are principally prescribed for treating wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,900 hospitals and managed directly by its 43 regional sales offices in China. Leveraging its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
About Majeton
Majeton, a wholly owned subsidiary of Essex Bio-Technology, is a sales, marketing and distribution company of therapeutics, medical devices and nutraceuticals for South East Asia. The company embraces innovation to provide a portfolio of first-in-class and best-in-class products with the aim to deliver solutions to commercial and clinical unmet needs, covering a wide range of therapeutic areas.
Media Enquiry:
Strategic Financial Relations Limited (Website: http://www.sprg.com.hk)
Shelly Cheng +852 2864 4857 shelly.cheng@sprg.com.hk
Yan Li +852 2114 4320 yan.li@sprg.com.hk
June Tuo +852 2864 4848 june.tuo@sprg.com.hk
Angela Shen +852 2864 4870 angela.shen@sprg.com.hk
Media: media@essex.com.cn
Investor Enquiry:
Investor Relations: investors@essex.com.cn
Topic: Press release summary
Source: Essex Bio-Technology Limited
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Essex Bio-Technology Limited |
| Feb 10, 2026 18:14 HKT/SGT |
|
EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong |
| Aug 26, 2025 20:00 HKT/SGT |
|
Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation |
| Aug 13, 2025 20:24 HKT/SGT |
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration |
| July 25, 2025 10:52 HKT/SGT |
|
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China |
| Mar 18, 2024 21:30 HKT/SGT |
|
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1% |
| Aug 16, 2023 19:06 HKT/SGT |
|
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22% |
| July 26, 2023 18:58 HKT/SGT |
|
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed |
| Apr 11, 2023 12:58 HKT/SGT |
|
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China |
| Mar 8, 2023 20:28 HKT/SGT |
|
Essex Bio-Technology Announces 2022 Annual Financial Results |
| Feb 22, 2023 18:48 HKT/SGT |
|
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration |
| More news >> |
 |
|
|
|
